Aurinia Pharmaceuticals Inc. (AUPH) company profile
Close on Nov 17, 2026Market cap $2.06BP/E 6.7Yield –
About Aurinia Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Aurinia is a biopharmaceutical company that develops and commercializes medical therapies for individuals affected by autoimmune conditions. The company's principal commercial product is voclosporin, branded as Lupkynis, an oral calcineurin inhibitor prescribed for adult patients suffering from active lupus nephritis. Additionally, the company is developing aritinercept, an investigational dual inhibitor targeting cytokines that regulate B-cell activity for autoimmune disorders. In the United States, Aurinia supplies Lupkynis directly to a specialty distributor alongside two specialty pharmacies. For international markets, it provides commercial inventory to its collaboration partner, Otsuka Pharmaceutical, which handles distribution across Europe and Japan.
The organization maintains a workforce of 128 full-time equivalent employees and utilizes external contract manufacturers for drug substance production, capsule encapsulation, and product packaging. Lupkynis holds regulatory approvals and commercial distribution across the United States, Japan, Switzerland, the United Kingdom, and the European Union, with licensing rights extending to additional territories including Norway, Iceland, and Ukraine. The text does not disclose the location of the company's corporate headquarters.
Summary of the business section of Aurinia Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Aurinia Pharmaceuticals Inc.
- Headquarters
- Edmonton, A0
- Address
- #140, 14315 - 118 Avenue T5L 4S6
- Phone
- (250) 744-2487
- Website
- auriniapharma.com
- Employees
- 128, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Edmonton, Canada
Stock & identifiers
- Ticker
- AUPH
- Exchange
- Nasdaq
- IPO date
- Sep 3, 2014
- Shares outstanding
- 134M, Oct 29, 2026
- Public float
- $1.00B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1600620
- CUSIP
- 05156V102
- ISIN
- US05156V1026
- FIGI
- BBG000BCRJM5
- Share class FIGI
- BBG001S68013
- LEI
- 5299008YP2BW4570ML28
- EIN
- 98-1231763
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Kevin Tang | Chief Executive Officer, Director | 13,044,106 |
| Peter Greenleaf | Chief Executive Officer, Director | 1,840,379 |
| Stephen P. Robertson | Chief Legal Officer | 576,981 |
| Ryan Cole | Chief Operating Officer | 116,144 |
| Michael S. Hearne | Chief Financial Officer | 116,144 |
| Greg Keenan | SVP, Chief Medical Officer | 154,449 |
| Joseph M. Miller | Chief Financial Officer | 576,421 |
| Matthew Maxwell Donley | Chief Operating Officer | 680,299 |
| Kathleen Goetz | Director | – |
| Craig A. Johnson | Director | 14,592 |
| Jeffrey Allen Bailey | Director | 22,775 |
| Tina Susan Nova | Director | – |
| Karen L. Smith | Director | 24,807 |
| David R.W. Jayne | Director | 56,499 |
| Jill Leversage | Director | 26,453 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $5.86M | $17.55M | $2.06M | $115 | $84 |
| FY2024 | $6.42M | $7.62M | $2.21M | $65 | $63 |
| FY2023 | $10.57M | $14.92M | $3.89M | $65 | $69 |
| FY2022 | $8.84M | -$8.90M | $3.28M | $31 | $70 |
| FY2021 | $1.24M | $16.34M | $718.16K | $165 | $92 |
| FY2020 | $10.68M | -$2.60M | $3.23M | $68 | $129 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Peter Greenleaf Former Chief Executive Officer | $822.88K | $1.97M | $2.19M | $864.02K | $13.18K | $5.86M | -9% |
| Joseph Miller Former Chief Financial Officer | $526.99K | $550.65K | $614.49K | $395.24K | $15.38K | $2.10M | -8% |
| Matthew Donley Former Chief Operating Officer | $567.64K | $559.60K | $624.48K | $425.73K | $59.64K | $2.24M | -11% |
| Gregory Keenan, M.D. Former Chief Medical Officer | $516.23K | $423.06K | $472.11K | $348.46K | $14.38K | $1.77M | +34% |
| Stephen Robertson Chief Legal Officer, Corporate Secretary and Chief Compliance Officer | $481.90K | $568.56K | $634.47K | $361.43K | $80.16K | $2.13M | -4% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of February 25, 2026, we had 128 full-time equivalent employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 11, 2026 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Apr 13, 2026 | Tender offer | Third-party tender offer for the company's shares |
See a number that looks wrong?